These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31126990)

  • 21. Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.
    Cangini D; Silimbani P; Cafaro A; Giannini MB; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):467-477. PubMed ID: 32955827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm: a 2-speed cure in the United States and European Union.
    Valentini CG; Pagano L
    Blood Adv; 2023 Nov; 7(22):7084-7086. PubMed ID: 37847911
    [No Abstract]   [Full Text] [Related]  

  • 23. Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation.
    Wang SY; Thomassen K; Kurch L; Opitz S; Franke GN; Bach E; Platzbecker U; Kayser S
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e579-e582. PubMed ID: 33795208
    [No Abstract]   [Full Text] [Related]  

  • 24. Tagraxofusp as first-line treatment for blastic plasmacytoid dendritic cell neoplasm.
    Díaz Acedo R; Domínguez Muñoz MÁ; Navajas Laguna C; Morales Camacho R; Simón Pilo I; Calama Ruiz-Mateos VP; Yébenes Ramírez M; Vahí Sánchez de Medina M; Artacho Criado S; Rodríguez Pérez A; Couto Caro MC
    Leuk Lymphoma; 2022 Jul; 63(7):1762-1764. PubMed ID: 35200083
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Zhang Y; Sokol L
    Cancer Manag Res; 2022; 14():2107-2117. PubMed ID: 35789956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting CD123 in BPDCN: an emerging field.
    DiPippo AJ; Wilson NR; Pemmaraju N
    Expert Rev Hematol; 2021 Nov; 14(11):993-1004. PubMed ID: 34607517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123.
    Hu X; Ediriwickrema A; Saleem A; Tan B; Pemmaraju N; Mannis GN
    Leuk Res; 2024 Apr; 139():107479. PubMed ID: 38492495
    [No Abstract]   [Full Text] [Related]  

  • 28. [Enhancer hijacking via disease-specific chromosomal translocation in blastic plasmacytoid dendritic cell neoplasm].
    Kubota S
    Rinsho Ketsueki; 2020; 61(1):47-51. PubMed ID: 32023603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blastic Plasmacytoid Dendritic Cell Neoplasm: The European Perspective.
    Deconinck E
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):613-620. PubMed ID: 32336424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Haddadin M; Taylor J
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):539-552. PubMed ID: 32336418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.
    Beziat G; Ysebaert L
    Onco Targets Ther; 2020; 13():5199-5205. PubMed ID: 32606740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report.
    Sibai J; Chen R; Nabhani IA; Perusini MA; Sibai H
    EJHaem; 2022 Nov; 3(4):1374-1376. PubMed ID: 36467820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of allogeneic hematopoietic stem cell transplantation in first complete remission for pediatric blastic plasmacytoid dendritic cell neoplasm with skin involvement: a case report and review of literature.
    Sakashita K; Saito S; Yanagisawa R; Tanaka M; Yoshikawa K; Hirabayashi K; Tsukahara K; Motobayashi M; Nakazawa Y; Koike K
    Pediatr Blood Cancer; 2013 Nov; 60(11):E140-2. PubMed ID: 23788509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promising results with tagraxofusp in BPDCN.
    Gourd E
    Lancet Oncol; 2019 Jun; 20(6):e295. PubMed ID: 31060793
    [No Abstract]   [Full Text] [Related]  

  • 35. A critical review of treatment modalities for blastic plasmacytoid dendritic cell neoplasm.
    Falcone U; Sibai H; Deotare U
    Crit Rev Oncol Hematol; 2016 Nov; 107():156-162. PubMed ID: 27823644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm - collected cases from a single center and case reports.
    Faustmann P; Schroeder JC; Mix L; Harland L; Riedel A; Vogel W; Lengerke C; Wirths S
    Front Oncol; 2024; 14():1384172. PubMed ID: 38665943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity.
    Lim MS; Lemmert K; Enjeti A
    BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for separate transformation to acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm from a shared ancestral hematopoietic clone.
    Luskin MR; Kim AS; Patel SS; Wright K; LeBoeuf NR; Lane AA
    Leuk Lymphoma; 2020 Sep; 61(9):2258-2261. PubMed ID: 32366145
    [No Abstract]   [Full Text] [Related]  

  • 39. Unique presentation of blastic plasmacytoid dendritic cell neoplasm: a single-center experience and literature review.
    Paluri R; Nabell L; Borak S; Peker D
    Hematol Oncol; 2015 Dec; 33(4):206-11. PubMed ID: 24850172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents.
    Wang S; Wang X; Liu M; Bai O
    Ann Hematol; 2018 Apr; 97(4):563-572. PubMed ID: 29455234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.